Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 12, 2010, Pages 1296-1309

  Panaccione, R ^a   Colombel, J F ^b   Sandborn, W J ^c   Rutgeerts, P ^d   D'Haens, G R ^e   Robinson, A M ^f   Chao, J ^f   Mulani, P M ^f   Pollack, P F ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c MAYO CLINIC   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e IMELDA HOSPITAL   (Belgium)

^f ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ABSCESS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAL ABSCESS; ARTHRALGIA; ARTICLE; BACTEREMIA; BASAL CELL CARCINOMA; BLADDER CANCER; BOWEN DISEASE; BREAST CANCER; BRONCHITIS; CAMPYLOBACTERIOSIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM INFECTION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEMALE; FEVER; GASTROENTERITIS; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; INFLUENZA; INJECTION SITE PAIN; INTESTINAL ABSCESS; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; LUNG CARCINOMA; LUNG EMBOLISM; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OROPHARYNX CANDIDIASIS; OTITIS MEDIA; OUTCOME ASSESSMENT; OVARY CANCER; PERIRECTAL ABSCESS; PERITONEUM ABSCESS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PSOAS ABSCESS; PYELONEPHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM ABSCESS; REMISSION; RHINOPHARYNGITIS; SCROTUM ABSCESS; SEPSIS; SINUSITIS; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; THRUSH; THYROID CANCER; TUBERCULOSIS; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; VIRUS INFECTION; WOUND INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952748486     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04304.x     Document Type: Article

References (41)

1. Louis E, Colard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001 49 : 777 782.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
4. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 333.
5. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med 2007 146 : 829 838.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
7. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 357 : 228 238.
8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease [published correction appears in N Engl J Med 2007; 357: 1357]. N Engl J Med 2007 357 : 239 250. (Pubitemid 47080388)
9. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371 : 660 667.
10. Sandborn WJ, Rutgeerts P, Reinisch W, et al. SONIC: A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy [abstract 1117]. Am J Gastroenterol 2008 103 (Suppl 1 S436.
11. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004 99 : 91 6.
12. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008 135 : 1493 1499.
13. Wu EQ, Yu AP, Tang J, et al. Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn's disease. Manag Care Interface 2008 21 : 20 3.
14. Loftus EV Jr., Johnson SJ, Yu AP, et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009 21 : 1302 1309.
15. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2007 24 : 319 328.
16. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009 58 : 940 948.
17. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56 : 1232 1239.
18. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009 104 : 1170 1179.
19. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008 103 : 3132 3141.
20. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994 106 : 287 296.
21. Colombel J-F, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009 15 : 1308 1319.
22. American Gastroenterological Association (AGA). American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology 2007 133 : 312 339.
23. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009 104 : 465 483.
24. Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab. Gastroenterology 2007 4 (Suppl 2 A-147.
25. D'Haens GR, Fedorak R, Lémann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis 2009 15 : 1599 1604.
26. Casellas F, Rodrigo L, Niño P, et al. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007 13 : 1395 1400.
27. Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008 53 : 1033 1041.
28. Poupardin C, Lemann M, Gendre JP, et al. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol 2006 30 : 247 252.
29. de Ridder L, Rings EHHM, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008 14 : 353 358.
30. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005 128 : 862 869.
31. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009 58 : 492 500.
32. Burmester GR, Mease P, Dijkmans BAC, et al. Adalimumab safety and mortality rates from trials of six immune mediated inflammatory diseases. Ann Rheum Dis 2009 68 : 1863 1869.
33. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009 30 : 265 274.
34. Yu AP, Johnson S, Wang S-T, et al. Cost utility of adalimumab versus infliximab maintenance. therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 2009 27 : 609 621.
35. Sandborn WJ, Colombel J-F, Rutgeerts P, et al. Benefits of dosage adjustment with adalimumab in Crohn's disease: an analysis of the CHARM trial. Gastroenterology 2008 4 (Suppl 1 A-347.
36. Loftus EV Jr., Pan X, Zurawski P, et al. Dosage pattern of adalimumab in real-world clinical practice and predictors of dosage increase in patients with Crohn's disease in the United States. Gastroenterology 2009 5 (Suppl 1 A-175.
37. Pan X, Zurawski P, Mulani P, et al. Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn's disease in the United States. J Manag Care Pharm 2009 15 : 173.
38. Wu EQ, Mulani PM, Yu A, et al. Loss of treatment response among Crohn's disease patients receiving infliximab maintenance therapy. Value Health 2008 11 : 820 829.
39. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007 13 : 1093 1099.
40. Louis E, Vernier-Massouille G, Grimaud J-C, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009 5 (Suppl 1 A-146.
41. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008 134 : 1861 1868.